Human Microbiome Market

Human Microbiome Market (Indication: Gastrointestinal & Metabolic Disorders, Women’s Health, Cancer, and Others; Technology and Therapeutic Area) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast, 2021-2028

Human Microbiome Market Outlook 2028

  • The global market was valued at US$ 1.3 Bn in 2020
  • It is estimated to expand at a CAGR of 7.1% from 2021 to 2028
  • The global human microbiome industry is expected to reach the value of US$ 2.2 Bn by the end of 2028

Analysts’ Viewpoint on Global  Market Scenario

Increasing gastrointestinal disorders, technological advancements, rising investments in human microbiome projects in developing countries, and lucrative presence of market players across the globe are factors responsible for the rapid expansion of global human microbiome market. The growing awareness about women health is also driving the global market for human microbiome. Market stakeholders are extending their services arms by developing innovative and technologically advanced products in order to gain revenue benefits. Market players operating in the global market should focus on the challenges associated with the clinical trial setbacks, some regulatory hurdles, and privacy Issues in diagnostics to stay afloat in the business. In addition, companies in the global human microbiome industry should accelerate their product development and unlock revenue opportunities to obtain competitive benefits.

Increase in Research & Development Activities in Human Microbiome Market

The microbiome is a genetic component of various microorganisms such as bacteria, fungi, protozoa, and viruses, which live inside and on the human body. The rising knowledge about the benefits of the bacteria present in the microbiome for better digestion of food, regulation of the immune system, and protection against other disease-causing bacteria is fueling the growth of the global human microbiome market. Manufacturers operating in the global market for human microbiomes are developing diagnostic and therapeutic products. The increasing research & development activities in the field of this market are contributing to the growth of the global human microbiome business.

Technological advancements in metagenomics and next-generation sequencing have made microbiome-based testing simple and cost-effective, paving the way to carry out rapid analysis of the genomic content of microorganisms from human samples. This has strengthened the development process for microbiome-based diagnostics. Gastrointestinal and metabolic disorders are likely to capture the leading share of the diagnostics market. Due to the rise in focus of companies toward developing an easy analysis platform for gut health-based disorders, such as irritable bowel syndrome and Crohn’s disease. Rising efforts by manufacturers to develop non-invasive tests create potential opportunities for market growth.

Request a sample to get extensive insights into the Human Microbiome Market

Metagenomic Sequencing Technology Generates Lucrative Revenue Benefits for Manufacturers

Among technologies, the global human microbiome market has been divided into metagenomic sequencing and 16s rRNA sequencing. The metagenomic sequencing segment is expected to account for the largest share of the global market for human microbiomes. This growth can be attributed to the rising penetration of small-scale product manufacturers across the globe. These players are engaged in providing comprehensive data profiles of the inherent microbiome of the individual being tested. There are rising investments by companies operating in the human microbiome industry. Increasing partnerships and collaborative activities by market players to offer technology-driven products are anticipated to propel the segment during the forecast period.

To understand how our report can bring a difference to your business strategy, Ask for a brochure

Rising Prevalence of Gastrointestinal and Metabolic Disorders Drive Market Growth

The growth of the global human microbiome market can be attributed to the increasing prevalence of gastrointestinal & metabolic disorders. The growing awareness about the severity of chronic diseases such as cancer driving the expansion of the global market. Major market players in the microbiome diagnostics segment are launching innovative products to cure several common gut problems, Crohn’s disease, and ulcerative colitis. The growth of the segment can be attributed to the high number of microbiome diagnostic companies and the ease of non-invasive testing provided by this method.

Stuck in a neck-to-neck competition with other brands? Request a custom report on Human Microbiome Market

Tremendous Growth Opportunities for North America Market Players

Due to the increase in investments in research & development, ongoing clinical trials for developing microbiome-based therapies, stringent governmental regulations, and rapid technological advancements, North America is expected to dominate the global market for human microbiomes in the upcoming years. The growing awareness about the benefits of microbiome-based products among consumers is escalating the demand for these products. A large number of market players working in North America is a major driving factor for the. The increasing efforts by governments to promote human microbiome products are contributing to the expansion of the North American market for human microbiome, creating value-grab opportunities for market players.

Human Microbiome Industry: Overview

  • According to Transparency Market Research’s latest report on the global market for the historical period, 2017–2019 and forecast period 2021–2028, technological advancements, mergers & collaborations, a rise in venture capital investments, and a surge in the financing of the microbiome projects are projected to drive the global human microbiome market during the forecast period

Increase in Industry-Institute Partnerships and High Unmet Medical Needs to Drive the Global Market

  • A significant number of microbiome therapeutics and diagnostics are targeted toward a market with large unmet medical needs. For instance, the present standard of care for Clostridium difficile infection (CDI) is a treatment with antibiotics. Antibiotic treatment can resolve acute infection; however, it also has the probability to worsen dysbiosis in patients. This makes them potentially more susceptible to the recurrence of CDI. Patients with recurrent CDI receive many rounds of antibiotics that could worsen dysbiosis, and hence, are more likely to face a relapse. Various key companies strive to resolve unmet medical needs for cancer, CNS disorders, women’s health disorders, skin disorders, and rare diseases through their microbiome-based products.
  • The human microbiome is still an emerging and extensive science. Collaborating with eminent scientists, researchers, and physicians in the field helps in enhancing a company’s go-to-market strategy. Industry-institute partnerships are thriving in the microbiome market and fueling growth. For instance, in 2020, Enterome collaborated with BIOASTER Institute to explore the mechanism of cancer immunotherapies that are microbiome-derived.

Clinical Trial Setbacks, Regulatory Hurdles, and Privacy Issues in Diagnostics to Hamper Market

  • The global microbiome market is in its nascent stage. Hence, the likelihood of unfavorable results from a clinical trial is a risk that could hamper the market growth. For instance, in 2016, Seres Therapeutics suffered a setback as its microbiome therapeutic SER-109 failed to overtake a placebo for reducing the risk of Clostridium difficile infection (CDI). However, the company is backed by a strong research team and aims to find a solution to the hurdle soon. Therefore, despite minor setbacks, expertise and advances in the microbiome market can help to offset the restraint.
  • Concerns over the privacy of subjects and sending stool or other samples for diagnostic testing are likely to restrain the global market. To draw an analogy, it is similar to the concern over 23andme’s genetic tests, where there were concerns in the public regarding the privacy and anonymity of their genetic data.

Human Microbiome Industry: Competition Landscape

  • This report profiles major players in the global market based on various attributes such as company overview, financial overview, product portfolio, business strategies, and recent developments
  • The global human microbiome business is highly fragmented, with the presence of a number of small, mid-size, and large prominent players
  • Leading players operating in the global human microbiome industry are
    • AOBiome
    • Enterome Biosciences SA
    • Metabiomics Corp. (BioSpherex LLC)
    • Microbiome Therapeutics LLC
    • Osel, Inc.
    • Rebiotix, Inc.
    • Second Genome
    • Seres Therapeutics
    • Synthetic Biologics, Inc.
    • Vedanta Biosciences
    • 4D Pharma
    • Ferring Pharmaceuticals, and other prominent players

Human Microbiome Market: Key Developments

  • Key players in the global human microbiome industry are focusing on technological advancements, a rise in investments in clinical trials, the surge in mergers & partnerships among key players, and high-unmet needs in the industry. These strategies are likely to fuel the growth of the global market. A few expansion strategies adopted by players operating in the global human microbiomes market are:
    • In April 2021, 4D pharma plc, a leading biotherapeutic company, participated in the Jefferies Microbiome-based Therapeutics Summit to showcase its product portfolio and offerings at the global level
    • In December 2021, 4D pharma plc, a leading developer of the microbiome new drug class also known as Live Biotherapeutic products (LBPs), announced its fecal microbiome analyses from the successful phase 2 trial of Blautix drug. This is widely recommended for the treatment of irritable bowel syndrome coupled with constipation and diarrhea.
    • In June 2021, ENTEROME SA, a clinical-stage biotechnology-driven company, announced the accomplishment and capabilities of its proprietary product GeneMark-HM software, which is highlighted in NAR Genomics and Bioinformatics publications
    • In April 2018, LEO Pharma entered into a partnership with microbiome-therapeutics company Naked Biome, Inc.
  • The report on the global human microbiome market discussed individual strategies, followed by company profiles of human microbiome services. The competitive landscape section has been included in the report to provide readers with a dashboard view and a company market share analysis of key players operating in the global market for human microbiome.

Market Snapshot

Attribute

Detail

Market Size Value in 2020

US$ 1.3 Bn

Market Forecast Value in 2028

US$ 2.2 Bn

Growth Rate (CAGR)

7.1% (Year-on-Year)

Forecast Period

2021–2028

Quantitative Units

US$ Mn for Value

Market Analysis

It includes cross-segment and regional-level analysis. Moreover, the qualitative analysis includes drivers, restraints, opportunities, key trends, and a parent industry overview.

Competition Landscape

  • Market share analysis by company (2020)
  • Company profiles section includes overview, product portfolio, sales footprint, key subsidiaries or distributors, strategy & recent developments, and key financials

Format

Electronic (PDF) + Excel

Market Segmentation

  • Indication
    • Gastrointestinal & Metabolic Disorders
    • Women’s Health
    • Cancer
    • Others
  • Technology
    • 16s rRNA Sequencing
    • Metagenomic Sequencing
  • Therapeutic Area
    • Gastrointestinal Disorders
    • Metabolic Disorders
    • Women’s Health
    • Skin Disorders
    • Others

Regions Covered

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Countries Covered

  • U.S.
  • Canada
  • Germany
  • U.K.
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Japan
  • China
  • India
  • Australia & New Zealand
  • Rest of Asia Pacific
  • Brazil
  • Mexico
  • Rest of Latin America
  • GCC Countries
  • South Africa
  • Rest of the Middle East & Africa

Companies Profiled

  • AOBiome
  • Enterome Biosciences SA
  • Metabiomics Corp. (BioSpherex LLC)
  • Microbiome Therapeutics LLC
  • Osel, Inc.
  • Second Genome
  • Seres Therapeutics
  • Synthetic Biologics, Inc.
  • Vedanta Biosciences
  • 4D Pharma
  • Ferring Pharmaceuticals

Customization Scope

Available upon request

Pricing

Available upon request

Human Microbiome Market – Segmentation

Indication
  • Gastrointestinal & Metabolic Disorders
  • Women’s Health
  • Cancer
  • Others
Technology
  • 16s rRNA Sequencing
  • Metagenomic Sequencing
Therapeutic Area
  • Gastrointestinal Disorders
  • Metabolic Disorders
  • Women’s Health
  • Skin Disorders
  • Others
Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

Frequently Asked Questions

What is the total market worth of human microbiome market?

The global market was worth US$ 1.3 Bn and is projected to reach a value of US$ 2.2 Bn by the end of 2028

What is the anticipated CAGR of the market for human microbiome in the forecast period?

The human microbiome market is anticipated to grow at a CAGR of 7.1% during the forecast period

Which region is expected to project the highest market share in the global market for human microbiome ?

North America accounted for a major share of the global market

What are the key driving factors for the growth of the global market for human microbiome?

Global market for human microbiome is driven by a rise in venture capital investments, and the surge in the financing of the microbiome projects is projected to drive the global market during the forecast period

Who are the key players in the global human microbiome industry?

Key players in the global market include AOBiome, Enterome Biosciences SA, Metabiomics Corp. (BioSpherex LLC), Microbiome Therapeutics LLC, Osel, Inc., Second Genome, Seres Therapeutics, Synthetic Biologics, Inc., Vedanta Biosciences, 4D Pharma, and Ferring Pharmaceuticals

    1. Preface

        1.1. Market Definition and Scope

        1.2. Market Segmentation

        1.3. Key Research Objectives

        1.4. Research Highlights

    2. Assumptions and Research Methodology

    3. Executive Summary: Global Human Microbiome Market

    4. Market Overview

        4.1. Introduction

            4.1.1. Market Definition

            4.1.2. Industry Evolution / Developments

        4.2. Overview

        4.3. Market Dynamics

            4.3.1. Drivers

            4.3.2. Restraints

            4.3.3. Opportunities

        4.4. Global Human Microbiome Market Analysis and Forecast, 2017–2028

            4.4.1. Market Revenue Projections (US$ Mn)

    5. Key Insights

        5.1. COVID-19 Impact on the Human Microbiome Market

        5.2. Microbiome Therapeutics Pipeline Scenario

        5.3. Regulatory Scenario across globe

        5.4. Impact of human microbiome therapeutics on current treatment options

        5.5. Key Mergers & Acquisitions

    6. Global Human Microbiome Market Analysis and Forecast, by Indication

        6.1. Introduction & Definition

            6.1.1. Key Findings / Developments

        6.2. Global Human Microbiome Market Value Forecast, by Indication, 2017–2028

            6.2.1. Gastrointestinal & Metabolic Disorders

            6.2.2. Women's Health

            6.2.3. Cancer

            6.2.4. Others

        6.3. Global Human Microbiome Market Attractiveness Analysis, by Indication

        6.4. Global Human Microbiome Market Analysis and Forecast, by Technology

            6.4.1. Introduction & Definition

            6.4.2. Key Findings / Developments

        6.5. Global Human Microbiome Market Value Forecast, by Technology, 2017–2028

            6.5.1. 16s rRNA Sequencing

            6.5.2. Metagenomic Sequencing

        6.6. Global Human Microbiome Market Attractiveness Analysis, by Technology

    7. Global Human Microbiome Market Analysis and Forecast, by Therapeutic Area

        7.1. Introduction & Definition

            7.1.1. Key Findings / Developments

        7.2. Global Human Microbiome Market Value Forecast, by Therapeutic Area, 2017–2028

            7.2.1. Gastrointestinal Disorders

            7.2.2. Metabolic Disorders

            7.2.3. Women's Health Disorders

            7.2.4. Skin Disorders

            7.2.5. Others

        7.3. Global Human Microbiome Market Attractiveness Analysis, by Therapeutic Area

    8. Global Human Microbiome Market Analysis and Forecast, by Region

        8.1. Key Findings

        8.2. Global Human Microbiome Market Value Forecast, by Region

            8.2.1. North America

            8.2.2. Europe

            8.2.3. Asia Pacific

            8.2.4. Latin America

            8.2.5. Middle East & Africa

        8.3. North America Human Microbiome Market Attractiveness Analysis, by Region

    9. North America Human Microbiome Market Analysis and Forecast

        9.1. Introduction

            9.1.1. Key Findings

        9.2. North America Human Microbiome Market Value (US$ Mn) Forecast, by Indication, 2017–2028

            9.2.1. Gastrointestinal & Metabolic Disorders

            9.2.2. Women's Health

            9.2.3. Cancer

            9.2.4. Others

        9.3. North America Human Microbiome Market Value (US$ Mn) Forecast, by Technology, 2017–2028

            9.3.1. 16s rRNA Sequencing

            9.3.2. Metagenomic Sequencing

        9.4. North America Human Microbiome Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2028

            9.4.1. Gastrointestinal Disorders

            9.4.2. Metabolic Disorders

            9.4.3. Women's Health Disorders

            9.4.4. Skin Disorders

            9.4.5. Others

        9.5. North America Human Microbiome Market Value (US$ Mn) Forecast, by Country, 2017–2028

            9.5.1. U.S.

            9.5.2. Canada

        9.6. North America Human Microbiome Market Attractiveness Analysis

            9.6.1. By Indication

            9.6.2. By Technology

            9.6.3. By Therapeutic Area

            9.6.4. By Country

    10. Europe Human Microbiome Market Analysis and Forecast

        10.1. Introduction

            10.1.1. Key Findings

        10.2. Europe Human Microbiome Market Value (US$ Mn) Forecast, by Indication, 2017–2028

            10.2.1. Gastrointestinal & Metabolic Disorders

            10.2.2. Women's Health

            10.2.3. Cancer

            10.2.4. Others

        10.3. Europe Human Microbiome Market Value (US$ Mn) Forecast, by Technology, 2017–2028

            10.3.1. 16s rRNA Sequencing

            10.3.2. Metagenomic Sequencing

        10.4. Europe Human Microbiome Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2028

            10.4.1. Gastrointestinal Disorders

            10.4.2. Metabolic Disorders

            10.4.3. Women's Health Disorders

            10.4.4. Skin Disorders

            10.4.5. Others

        10.5. Europe Human Microbiome Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

            10.5.1. Germany

            10.5.2. U.K.

            10.5.3. France

            10.5.4. Italy

            10.5.5. Spain

            10.5.6. Rest of Europe

        10.6. Europe Human Microbiome Market Attractiveness Analysis

            10.6.1. By Indication

            10.6.2. By Technology

            10.6.3. By Therapeutic Area

            10.6.4. By Country/Sub-region

    11. Asia Pacific Human Microbiome Market Analysis and Forecast

        11.1. Introduction

            11.1.1. Key Findings

        11.2. Asia Pacific Human Microbiome Market Value (US$ Mn) Forecast, by Indication, 2017–2028

            11.2.1. Gastrointestinal & Metabolic Disorders

            11.2.2. Women's Health

            11.2.3. Cancer

            11.2.4. Others

        11.3. Asia Pacific Human Microbiome Market Value (US$ Mn) Forecast, by Technology, 2017–2028

            11.3.1. 16s rRNA Sequencing

            11.3.2. Metagenomic Sequencing

        11.4. Asia Pacific Human Microbiome Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2028

            11.4.1. Gastrointestinal Disorders

            11.4.2. Metabolic Disorders

            11.4.3. Women's Health Disorders

            11.4.4. Skin Disorders

            11.4.5. Others

        11.5. Asia Pacific Human Microbiome Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

            11.5.1. China

            11.5.2. Japan

            11.5.3. India

            11.5.4. Australia & New Zealand

            11.5.5. Rest of Asia Pacific

        11.6. Asia Pacific Human Microbiome Market Attractiveness Analysis

            11.6.1. By Indication

            11.6.2. By Technology

            11.6.3. By Therapeutic Area

            11.6.4. By Country/Sub-region

    12. Latin America Human Microbiome Market Analysis and Forecast

        12.1. Introduction

            12.1.1. Key Findings

        12.2. Latin America Human Microbiome Market Value (US$ Mn) Forecast, by Indication, 2017–2028

            12.2.1. Gastrointestinal & Metabolic Disorders

            12.2.2. Women's Health

            12.2.3. Cancer

            12.2.4. Others

        12.3. Latin America Human Microbiome Market Value (US$ Mn) Forecast, by Technology, 2017–2028

            12.3.1. 16s rRNA Sequencing

            12.3.2. Metagenomic Sequencing

        12.4. Latin America Human Microbiome Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2028

            12.4.1. Gastrointestinal Disorders

            12.4.2. Metabolic Disorders

            12.4.3. Women's Health Disorders

            12.4.4. Skin Disorders

            12.4.5. Others

        12.5. Latin America Human Microbiome Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

            12.5.1. Brazil

            12.5.2. Mexico

            12.5.3. Rest of Latin America

        12.6. Latin America Human Microbiome Market Attractiveness Analysis

            12.6.1. By Indication

            12.6.2. By Technology

            12.6.3. By Therapeutic Area

            12.6.4. By Country/Sub-region

    13. Middle East & Africa Human Microbiome Market Analysis and Forecast

        13.1. Introduction

            13.1.1. Key Findings

        13.2. Middle East & Africa Human Microbiome Market Value (US$ Mn) Forecast, by Indication, 2017–2028

            13.2.1. Gastrointestinal & Metabolic Disorders

            13.2.2. Women's Health

            13.2.3. Cancer

            13.2.4. Others

        13.3. Middle East & Africa Human Microbiome Market Value (US$ Mn) Forecast, by Technology, 2017–2028

            13.3.1. 16s rRNA Sequencing

            13.3.2. Metagenomic Sequencing

        13.4. Middle East & Africa Human Microbiome Market Value (US$ Mn) Forecast, by Therapeutic Area, 2017–2028

            13.4.1. Gastrointestinal Disorders

            13.4.2. Metabolic Disorders

            13.4.3. Women's Health Disorders

            13.4.4. Skin Disorders

            13.4.5. Others

        13.5. Middle East & Africa Human Microbiome Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

            13.5.1. GCC Countries

            13.5.2. South Africa

            13.5.3. Rest of Middle East & Africa

        13.6. Latin America Human Microbiome Market Attractiveness Analysis

            13.6.1. By Indication

            13.6.2. By Technology

            13.6.3. By Therapeutic Area

            13.6.4. By Country/Sub-region

    14. Competition Landscape

        14.1. Market Player - Competition Matrix (by tier and size of companies)

        14.2. Market Share / Position Analysis, by Company, 2020

        14.3. Company Profiles

            14.3.1. AOBiome

                14.3.1.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.1.2. Product Portfolio

                14.3.1.3. Strategic Overview

                14.3.1.4. SWOT Analysis

            14.3.2. Enterome Biosciences SA

                14.3.2.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.2.2. Product Portfolio

                14.3.2.3. Strategic Overview

                14.3.2.4. SWOT Analysis

            14.3.3. Metabiomics Corp. (BioSpherex LLC)

                14.3.3.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.3.2. Product Portfolio

                14.3.3.3. Strategic Overview

                14.3.3.4. SWOT Analysis

            14.3.4. Microbiome Therapeutics LLC

                14.3.4.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.4.2. Product Portfolio

                14.3.4.3. Strategic Overview

                14.3.4.4. SWOT Analysis

            14.3.5. Osel, Inc.

                14.3.5.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.5.2. Product Portfolio

                14.3.5.3. Strategic Overview

                14.3.5.4. SWOT Analysis

            14.3.6. Second Genome

                14.3.6.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.6.2. Product Portfolio

                14.3.6.3. Strategic Overview

                14.3.6.4. SWOT Analysis

            14.3.7. Seres Therapeutics

                14.3.7.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.7.2. Product Portfolio

                14.3.7.3. Financial Overview

                14.3.7.4. Strategic Overview

                14.3.7.5. SWOT Analysis

            14.3.8. Synthetic Biologics, Inc.

                14.3.8.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.8.2. Product Portfolio

                14.3.8.3. Financial Overview

                14.3.8.4. Strategic Overview

                14.3.8.5. SWOT Analysis

            14.3.9. Vedanta Biosciences

                14.3.9.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.9.2. Product Portfolio

                14.3.9.3. Financial Overview

                14.3.9.4. Strategic Overview

                14.3.9.5. SWOT Analysis

            14.3.10. 4D Pharma

                14.3.10.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.10.2. Product Portfolio

                14.3.10.3. Financial Overview

                14.3.10.4. Strategic Overview

                14.3.10.5. SWOT Analysis

            14.3.11. Ferring Pharmaceuticals

                14.3.11.1. Company Overview (HQ, Business Segments, Employee Strength)

                14.3.11.2. Product Portfolio

                14.3.11.3. Financial Overview

                14.3.11.4. Strategic Overview

                14.3.11.5. SWOT Analysis

    List of Table

    Table 1: Key Mergers and Acquisitions

    Table 2: Global Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 2017–2028

    Table 3: Global Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 2017–2028

    Table 4: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2028

    Table 5: Global Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Region, 2017-2028

    Table 6: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Region, 2020-2028

    Table 7: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication, 2017–2028

    Table 8: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology, 2017–2028

    Table 9: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country, 2017–2028

    Table 10: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2026

    Table 11: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020–2028

    Table 12: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 2017–2028

    Table 13: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 2017–2028

    Table 14: Europe Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

    Table 15: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2028

    Table 16: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country, 2020–2028

    Table 17: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Indication, 2017–2028

    Table 18: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Technology, 2017–2028

    Table 19: Asia Pacific Human Microbiome Diagnostic Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

    Table 20: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2028

    Table 21: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020–2028

    Table 22: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication, 2017–2028

    Table 23: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology, 2017–2028

    Table 24: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

    Table 25: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2028

    Table 26: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020–2028

    Table 27: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Indication, 2017–2028

    Table 28: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Technology, 2017–2028

    Table 29: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2017–2028

    Table 30: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Therapeutic Area, 2020–2028

    Table 31: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, by Country/Sub-region, 2020–2028

    List of Figure

    Figure 1: Global Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2017–2028

    Figure 2: Global Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2017–2028

    Figure 3: Human Microbiome Diagnostic Market Value Share, by Indication, 2020

    Figure 4: Human Microbiome Diagnostic Market Value Share, by Technology, 2020

    Figure 5: Human Microbiome Therapeutics Market Value Share, by Therapeutic Area, 2020

    Figure 6: Human Microbiome Therapeutics Market Value Share, by Region, 2020

    Figure 7: Global Human Microbiome Diagnostic Market Value Share Analysis, by Indication, 2020 and 2028

    Figure 8: Global GI & Metabolic Disorders Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2028

    Figure 9: Global Women’s Health Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2028

    Figure 10: Global Cancer Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2028

    Figure 11: Global Others Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2028

    Figure 12: Global Human Microbiome Diagnostic Market Attractiveness Analysis, by Indication, 2021-2028

    Figure 13: Global Human Microbiome Diagnostic Market Value Share Analysis, by Technology, 2020 and 2028

    Figure 14: Global Human Microbiome Diagnostic Market Attractiveness Analysis, by Technology, 2021-2028

    Figure 15: Global Metagenomic Sequencing Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2028

    Figure 16: Global 16s rRNA Sequencing Market Size (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2028

    Figure 17: Global Human Microbiome Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2028

    Figure 18: Global GI Disorders Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2028

    Figure 19: Global Metabolic Disorders Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2028

    Figure 20: Global Women’s Health Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2028

    Figure 21: Global Skin Disorders Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2028

    Figure 22: Global Others Market Size (US$ Mn) and Y-o-Y Growth (%), 2020–2028

    Figure 23: Global Human Microbiome Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2021-2028

    Figure 24: Global Human Microbiome Diagnostics Market Value Share Analysis, by Region, 2020 and 2028

    Figure 25: Global Human Microbiome Therapeutics Market Value Share Analysis, by Region, 2020 and 2028

    Figure 26: Global Human Microbiome Diagnostics Market Attractiveness Analysis, by Region, 2021-2028

    Figure 27: Global Human Microbiome Therapeutics Market Attractiveness Analysis, by Region, 2021-2028

    Figure 28: North America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2017–2028

    Figure 29: North America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2017–2028

    Figure 30: North America Diagnostics Market Attractiveness Analysis, by Country, 2021-2028

    Figure 31: North America Therapeutics Market Attractiveness Analysis, by Country, 2021-2028

    Figure 32: North America Diagnostic Market Value Share Analysis, by Indication, 2020 and 2028

    Figure 33: North America Diagnostic Market Value Share Analysis, by Technology, 2020 and 2028

    Figure 34: North America Diagnostic Market Value Share Analysis, by Country, 2020 and 2028

    Figure 35: North America Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2028

    Figure 36: North America Therapeutics Market Value Share Analysis, by Country, 2020 and 2028

    Figure 37: North America Diagnostics Market Attractiveness Analysis, by Indication, 2021-2028

    Figure 38: North America Diagnostics Market Attractiveness Analysis, by Technology, 2021-2028

    Figure 39: North America Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2021-2028

    Figure 40: Europe Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2017–2028

    Figure 41: Europe Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2017–2028

    Figure 42: Europe Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2021-2028

    Figure 43: Europe Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2021-2028

    Figure 44: Europe Diagnostic Market Value Share Analysis, by Indication, 2020 and 2028

    Figure 45: Europe Diagnostic Market Value Share Analysis, by Technology, 2020 and 2028

    Figure 46: Europe Diagnostic Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

    Figure 47: Europe Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2028

    Figure 48: Europe Therapeutics Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

    Figure 49: Europe Diagnostics Market Attractiveness Analysis, by Indication, 2021-2028

    Figure 50: Europe Diagnostics Market Attractiveness Analysis, by Technology, 2021-2028

    Figure 51: Europe Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2021-2028

    Figure 52: Asia Pacific Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2017–2028

    Figure 53: Asia Pacific Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2017–2028

    Figure 54: Asia Pacific Diagnostics Market Attractiveness Analysis, by Country, 2021-2028

    Figure 55: Asia Pacific Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2021-2028

    Figure 56: Asia Pacific Diagnostic Market Value Share Analysis, by Indication, 2020 and 2028

    Figure 57: Asia Pacific Diagnostic Market Value Share Analysis, by Technology, 2020 and 2028

    Figure 58: Asia Pacific Diagnostic Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

    Figure 59: Asia Pacific Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2028

    Figure 60: Asia Pacific Therapeutics Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

    Figure 61: Asia Pacific Diagnostics Market Attractiveness Analysis, by Indication, 2021-2028

    Figure 62: Asia Pacific Diagnostics Market Attractiveness Analysis, by Technology, 2021-2028

    Figure 63: Asia Pacific Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2021-2028

    Figure 64: Latin America Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2017–2028

    Figure 65: Latin America Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2017–2028

    Figure 66: Latin America Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2021-2028

    Figure 67: Latin America Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2021-2028

    Figure 68: Latin America Diagnostics Market Value Share Analysis, by Indication, 2020 and 2028

    Figure 69: Latin America Diagnostics Market Value Share Analysis, by Technology, 2020 and 2028

    Figure 70: Latin America Diagnostics Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

    Figure 71: Latin America Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2028

    Figure 72: Latin America Therapeutics Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

    Figure 73: Latin America Diagnostics Market Attractiveness Analysis, by Indication, 2021-2028

    Figure 74: Latin America Diagnostics Market Attractiveness Analysis, by Technology, 2021-2028

    Figure 75: Latin America Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2021-2028

    Figure 76: Middle East & Africa Human Microbiome Diagnostics Market Size (US$ Mn) Forecast, 2017–2028

    Figure 77: Middle East & Africa Human Microbiome Therapeutics Market Size (US$ Mn) Forecast, 2017–2028

    Figure 78: Middle East & Africa Diagnostics Market Attractiveness Analysis, by Country/Sub-region, 2021-2028

    Figure 79: Middle East & Africa Therapeutics Market Attractiveness Analysis, by Country/Sub-region, 2021-2028

    Figure 80: Middle East & Africa Diagnostics Market Value Share Analysis, by Indication, 2020 and 2028

    Figure 81: Middle East & Africa Diagnostics Market Value Share Analysis, by Technology, 2020 and 2028

    Figure 82: Middle East & Africa Diagnostics Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

    Figure 83: Middle East & Africa Therapeutics Market Value Share Analysis, by Therapeutic Area, 2020 and 2028

    Figure 84: Middle East & Africa Therapeutics Market Value Share Analysis, by Country/Sub-region, 2020 and 2028

    Figure 85: MEA Diagnostics Market Attractiveness Analysis, by Indication, 2021-2028

    Figure 86: MEA Diagnostics Market Attractiveness Analysis, by Technology, 2021-2028

    Figure 87: MEA Therapeutics Market Attractiveness Analysis, by Therapeutic Area, 2021-2028

Copyright © Transparency Market Research, Inc. All Rights reserved